Analytical Testing

Peak Tailing and Fronting in Peptide HPLC

Why chromatographic peaks become asymmetric and how overload, secondary interactions, and system effects alter peptide results.

TSMS Labs· 11 min· Published Jul 31, 2026

Peak Tailing and Fronting in Peptide HPLC

Ideal chromatographic peaks are approximately symmetrical. Real peptide peaks may tail, front, split, or broaden.

Peak tailing

Tailing produces an extended trailing edge. Potential causes include:

  • secondary interactions with residual silanols
  • inappropriate mobile-phase pH
  • adsorption to active sites
  • dead volume
  • slow mass transfer
  • sample degradation
  • mixed conformations

Tailing can hide late-eluting impurities and make integration less reproducible.

Peak fronting

Fronting produces a broadened leading edge. Common causes include column overload, sample-solvent mismatch, or bed disturbance.

Peak splitting

Split peaks may arise from:

  • incompatible injection solvent
  • partially blocked frits
  • voids
  • multiple peptide conformations
  • on-column reaction
  • sample heterogeneity

Diagnostic approach

Review:

  • sample concentration
  • injection volume
  • blank
  • reference standard
  • column history
  • connections
  • mobile-phase preparation
  • temperature
  • pressure profile

Frequently asked questions

Is tailing only a cosmetic problem?

No. It can impair impurity resolution and quantitation.

Can reducing injection amount help?

Yes, when overload is the cause.

Does a new column always solve peak-shape problems?

No. The cause may be mobile phase, instrument plumbing, or sample chemistry.

Can peptide conformation affect peak shape?

Yes. Slow interconversion can produce broad or split peaks.

Key takeaways

Peak shape is a diagnostic signal. Tailing, fronting, and splitting should be investigated because they can compromise specificity, resolution, and quantitative reliability.

References

  1. ICH Q2(R2). Validation of Analytical Procedures.
  2. ICH Q14. Analytical Procedure Development.
  3. FDA. Analytical Procedures and Methods Validation for Drugs and Biologics.

TSMS Labs educational disclaimer: For laboratory research and educational purposes only. Not for human consumption. This content is not medical, clinical, or regulatory advice.